COA truth and COA limits
A certificate of analysis can show measured results for a sample. It does not automatically prove the whole batch was sampled correctly, stored correctly, produced under GACP, or acceptable for an EU medicinal route.
Buyer-facing COA review must connect the result to the batch record, sampling record, lab method and contaminant risk profile.
Core testing categories
The exact panel depends on route and buyer requirements, but serious review commonly looks at:
- Cannabinoid profile and potency
- Microbiological quality
- Pesticide residues
- Heavy metals
- Residual solvents where processing creates relevance
- Mycotoxins and foreign matter risk where applicable
- Water activity or moisture where storage stability matters
Platform implication
The platform should not display COAs as isolated PDFs. It should bind them to sample ID, batch ID, lab, method, date, result status and any deviation or retest explanation.
GACP/GMP feasibility check
COA links to controlled sample and batch identity.
Evidence: Sampling record, chain of custody, COA, batch record.
COA exists but sampling plan or batch linkage is weak.
Evidence: Gap log and resampling decision.
Medicinal route requires validated methods or qualified lab expectations.
Evidence: Lab qualification, method review, importer testing plan.
